Overview

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection
Phase:
N/A
Details
Lead Sponsor:
Guo-Qing Jiang
Treatments:
Apixaban
Dalteparin
Dipyridamole
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin